Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 6/20 | 0.37 |
| ▸ | RAB9A | P51151 | 6/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.35 |
| ▸ | RELA | Q04206 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27607302 | 0.78 | HDAC4 (0.51) | HDAC4SCN9AMEN1KMT2ANPC1 | |
| SCHEMBL1186172 | 0.78 | ESR1 (0.46) | HDAC4SCN9AMEN1KMT2ANPC1 | |
| SCHEMBL5836419 | 0.78 | SCN9A (0.43) | HDAC4SCN9AMEN1KMT2ANPC1 | |
| SCHEMBL9288053 | 0.78 | ENPP3 (0.47) | HDAC4METAP2SCN9AMEN1KMT2A | |
| SCHEMBL1646055 | 0.78 | HDAC4 (0.44) | HDAC4METAP2SCN9AMEN1KMT2A | |
| SCHEMBL648786 | 0.77 | SCN9A (0.53) | HDAC4SCN9AMEN1KMT2ANPC1 | |
| SCHEMBL17794305 | 0.76 | SCN9A (0.53) | GAAMETAP2SCN9AMEN1KMT2A | |
| SCHEMBL3193030 | 0.76 | LMNA (0.43) | HDAC4SCN9ANPC1RAB9AMAPT | |
| SCHEMBL27243996 | 0.75 | SCN9A (0.47) | HDAC4SCN9AMEN1KMT2AKDM4E | |
| SCHEMBL16159580 | 0.75 | SCN9A (0.41) | HDAC4SCN9ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| WO-2014072903-A1 | NOVEL AMINOMETHYL-PHENOL DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-05-15 | — | — | WO | disclosed |
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| WO-2006048727-A1 | PIPERAZINYLPHENALKYL LACTAM/AMINE LIGANDS FOR THE 5HT1B RECEPTOR | PFIZER PRODUCTS INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-6949536-B2 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | disclosed |
| CN-1582287-A | Thiophenylthiopyrane dioxides as MMP or TNF-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-02-16 | — | — | CN | disclosed |
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | disclosed |
| US-20040157824-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | PFIZER INC. | 2004-08-12 | — | — | US | disclosed |
| US-6294558-B1 | ANTIINFLAMMATORY AGENTS AND PROSTAGLANTINS | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1086097-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER INC. (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-0921800-A4 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL MYERS SQUIBB CO (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999064415-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-12-16 | — | — | WO | disclosed |
| EP-0921800-A1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-16 | — | — | EP | disclosed |
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | disclosed |
| US-5827869-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-10-27 | — | — | US | disclosed |
| WO-1997029748-A1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-21 | — | — | WO | disclosed |
| US-5612359-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| EP-0702012-A1 | Substituted isoxazole sulfonamides and their use as endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | PTPN11, PTPN1, PTPN3 | HDAC4 1065/4885GAA 818/4885METAP2 3760/4885 |
| US-20040157824-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGS1, PTGER1 | HDAC4 1021/4885GAA 4715/4885METAP2 3527/4885 |
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | TNF, MMP9, MMP1 | HDAC4 1530/4885GAA 364/4885METAP2 179/4885 |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | HDAC4 797/4885GAA 3441/4885METAP2 852/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | HDAC4 797/4885GAA 3441/4885METAP2 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.